Subject Index

Note: Page numbers followed by “f” indicate figures; those followed by “t” indicate tables.

A
Absorption
    colonic, 261, 275, 276f, 277–279, 277f, 278f, 286
    gastrointestinal
        of fluid, 134, 135f, 136, 138, 145
        oral rehydration solution formulation
        and, 70–71
        sodium. See Sodium chloride, absorption of
Accessory cholera enterotoxin, 139, 268
Acetate
    from carbohydrate fermentation in colon, 272, 273, 287
    sodium absorption in ileum and, 286
Acetorphan, 151
Acetylcholine, colonic action of, 267
Acidosis, in acute diarrhea, 242
Acquired immunodeficiency syndrome (AIDS)
    diarrhea with, 6–7
    antimicrobial treatment of, 248–249
    weight loss in, energy intake and, 221, 222f
Activating protein-1, in interventions for anorexia, 175, 179
Acute phase response, anorexia in, 171, 223
Adenosine triphosphate pumps, 162–163
Adenylyl cyclase, cholera toxin action and, 138, 139
Adiposity signal, leptin as, 34
Adolescents
    behavioral therapy in, for control of obesity, 120
    type 2 diabetes in, 99
Adrenergic receptors, colonic sodium absorption and, 266
Afferent nerves
    hepatic, food intake regulation and, 211
African Americans, obesity development in, 201
Age
    chronic diarrhea and, 2
    obesity and, etiology of, 199
Agouti peptide, in hypothalamus, 50–51
Agouti-related peptide, 45, 50, 51; 235
    for experimental anorexia, 229
    as target for weight loss drug development, 124
L-Alanine, in oral rehydration solutions, 70, 71, 72
Albendazole, for infectious diarrhea, 249
Aldosterone, colonic absorptive capacity and, 266, 275
Allergies, diarrhea and, 28–29
Alosetron, intestinal secretions and, in cholera, 142
Amebiasis, antimicrobial treatment of, 248
Amino acids, in oral rehydration solutions, 70, 71, 72, 245
Amylase-resistant starch
    colonic absorption of, 277–279, 277f, 278f, 285
    colonic fermentation of, 272–273
    in oral rehydration solutions, 77, 246–247, 250, 285
Anaphylaxis, intestinal fluid secretion and, 144–145, 148
Androgens, weight loss with, 123
Angiotensin II, colonic absorptive capacity and, 266, 275

293
2,5-Anhydro-D-mannitol, 211
Anion exchange, 163
Anion exchanger type 1, colonic chloride transport and, 264
Anorexia
   acute phase response and, 171, 223
   brain-gut axis in, 31–39
   in cancer cachexia, 43, 44
   5-hydroxytryptamine antagonists for, 228–229, 234
   brain-gut axis in, 38
   neuropeptide Y system in, 229, 233
carbohydrate and, 232
consequences of, 221, 223
corticotropin-releasing factor and, 31–34, 181, 189–190, 209, 235
cytokines and, 172f, 173–175
pharmacologic control of, 176–181
   pro-inflammatory, 223–225, 224f
   signaling of, immunomodulators of, 225–226
discussion of, 232–240
   gastrointestinal dysfunction and, 31–34
   hormonal and neuropeptide mediators of, 226–230, 228f
   immunomodulators of, 225–226
   mechanisms of, 171–174, 172f, 223–225
   models of, 171, 173
   persistent, with diarrhea, 236–237
   pharmacologic control of, 172f, 234
      in cancer cachexia, 228–229
      neurochemical pathways of, 180–182
      via cytokine intracellular signaling, 176–181
      via cytokine membrane binding, 175–176
      in psychiatric conditions, 236
      as symptom, 191
tumor necrosis factor-α antagonists and, 233, 234
Antibiotics
   for chronic diarrhea, 3, 14, 15
   for infectious diarrhea, 247–249
vs. oral rehydration, for diarrhea and dysentery, 5–6
resistance to, in salmonella
gastroenteritis, 28
for salmonella diarrhea, 28
for shigellosis, 5–6
for small bowel bacterial overgrowth in diarrhea, 16
Antidepressant therapy, for irritable bowel syndrome, 33
Anti-emetics, and anorexia, 235
Anxiety, irritable bowel syndrome and, 33
Appetite (feeding). See also Energy homeostasis; Satiety
   in acute illness, 239–240
   glucose-sensing neurons and, 55
   hypothalamic influences on, 45–47
   increased, with corticosteroids, 239
   orexins and, 52–53, 54f
   regulation of, 107–110, 122. See also Food intake, regulation of orexin activity and, 53
Aquaporin water channels, colonic, 263
Arcuate nucleus, 45–47, 46f
neuropeptide Y neurons in, 48–50, 49f
Arginine vasopressin, water balance control and, 160
Astressin, 32
Athletes, energy intake in, 216
Atropine, 105, 106
Autonomic nervous system, in food intake regulation, 206
Average daily metabolic rate, in men and women, 197
Azithromycin, for cryptosporidiosis diarrhea, 249

B
Bacterial flora, colonic, 272, 286, 287
Bacterial infections
   in developing and developed countries, 21–22
   microvillus membrane injury by, 146
   models of, 171
Bacterial lipopolysaccharides. See Lipopolysaccharide(s)
Bacterial overgrowth, of small bowel, in chronic diarrhea, 15–16
SUBJECT INDEX

Bananas, green, colonic absorption and, 279, 286–287, 288

Behavior therapy, for control of obesity, 119–120

Bicarbonate
  in oral rehydration solutions, 83, 84
  secretion of, 164
  colonic, 265, 273
  duodenal, 164
  pancreatic, 105, 107

Bifidobacteria, diarrhea and, 26

Birth weight
  diabetes risk and, 101–102
  in Latin America, 100
  low, 291
  diarrhea in infants and, 27–28

Blood-brain barrier, in hypothalamus, 46

Blood glucose
  in diabetes
    brain-gut signaling and, 42–43
    gastroparesis and, 37–38
  food intake regulation and, 208, 210

Body composition, post-anorexia, 192, 193

Body fat
  accumulation and distribution of, 218, 219
  leptin in, 198–199
  gender differences in, 198
  reduction and control of, 119–131

Body mass index, 121–122

Body temperature, anorexia and, 223

Body weight
  pregnancy and, 203, 204f
  quality of life and, 129

Bombesin, 64, 113

Bombesin-like peptide, as satiety signal, 108

Brain
  in diabetes, changes in, 43
  signals to, about energy status, 55–59.
  See also Central nervous system

Brain capillary endothelial cells, in anorectic response, 174, 178, 179

Brain-gut axis
  in anorexia, 31–39
  in cancer cachexia-anorexia syndrome, 38
  in gastrointestinal dysfunction, 31–39

Brain-nutrient islet axis, 36

Breastfeeding
  childhood obesity, in Chile, 100
  childhood obesity and, 121, 219
  dehydration with, 27
  of infants with acute diarrhea, 249–250

Bumetanide, colonic bicarbonate secretion and, 265

Bupropion, weight loss with, 123

Butyrate
  carbohydrate fermentation in colon and, 272, 273, 286
  colonic absorption with, 277–278, 277f, 287
  effects of, 286, 287

C

Cachexia
  cancer, 43, 44
    5-HT antagonists for, 228–229, 234
    brain-gut axis in, 38
    neuropeptide Y system in, 233
    leptin levels and, 66
    vs. starvation, 191

Calcium
  dietary
    body mass index and, 121–122
    weight loss and, 121–122, 127
    ionized cytosolic, in regulation of ion flux, 164–165

Calcium-activated chloride channels, in colon, 265

Calcium antagonists, for anorexia, 177–178, 191

Calcium/calmodulin-dependent kinase, colonic sodium absorption and, 266

Calories
  in acute diarrhea, 250
  in obesity control, 120
  restricted, potential health benefits of, 239
  total and from fat, in Latin America, 90t, 91
Cancer
anorexia-cachexia with, 43, 44
5-HT antagonists for, 228–229, 234
brain-gut axis in, 38
neuropeptide Y system in, 233
deaths from, in Latin America, 91, 92f
models of, cancer cachexia and, 44
weight loss in, 221
Cannabinoid receptors, dietary fat intake and, 66
Carbohydrate(s)
colic fermentation of, 272–273, 288, 289
in experimental anorexia, 232
food intake regulation and, 110, 210
in obesity control, 121
Cardiovascular disease
in Latin America, 96–97
risk factors for, 97
Cation exchange, 163
CD14, in interventions for anorexia, 175–176
Cefixime, for shigella diarrhea, 248
Central nervous system
brain-gut axis of, in anorexia, 31–39
glucose-sensing neurons of, in feeding regulation, 55
signaling in about anorexia, 179–180, 225–226
about energy status, 55–59. See also Energy homeostasis
Cerebrovascular disease, in Latin America, 91, 92f
Children
diarrhea in acute, 241–260
chronic, 1–16
fluid and electrolyte balance in, 155–170
gastroenteritis in, 20–23
causes of, 21–22, 21f, 22f
in developing and developed countries, 21–22, 21f, 22f
nutritional status and, 23
transmission of, 22
intravenous fluid therapy in, 242–243, 260
malnourished
dehydration in, 245–246, 246t
diarrhea in, 3, 5, 5f, 12, 23, 23t
kidney function in, 168
in Latin America, 89
oral rehydration solutions in, 73, 75–77, 76f, 77f. See also Oral rehydration solutions
treatment options for, 258
obesity in, 95–96, 100–101, 199, 219, 291, 292
Chile
diabetes in, in adolescents, 99
obesity in, 95–96, 100
Chloride absorption of colonic, 261
small intestine, 163–164
secretion of, 136, 137f, 138, 164
transport of, colonic, 264, 276f
Chloride-bicarbonate exchanger, in fluid balance, 134, 135f
Chloride channels, in colon, 264, 265
Cholecystokinin actions of, 106f
in energy homeostasis, 48
as food-inhibiting drug, 116
leptin release and, 34–35
pancreatic enzyme secretion regulated by, 106
receptors of, 109, 115, 116, 117
release of, fatty acid stimulation of, 105, 106, 114
as satiety signal postprandial, 208
Cholera diarrhea in antimicrobial treatment of, 248
colic absorption in, 268, 277–279, 277f–278f
oral rehydration solutions for, 72, 73, 76–77. See also Oral rehydration solutions
composition of, 243–245, 244t, 245t
with resistant starch, 246–247, 285
as model for secretory diarrhea, 69
water supply and, 22
Cholera toxin
chloride ion secretion and, 138
enteric nervous system activity and, 141–142
enterotoxins produced by, 138, 139
intestinal endogenous secretagogues activated by, 139–140
Cholinergic system, pancreatic enzyme secretion regulation by, 105, 106
Circumventricular organs, cytokine synthesis by, 226
Citrate, in oral rehydration solutions, 83, 84
Clarithromycin, for cryptosporidiosis diarrhea, 249
Climate, obesity and, 218
Clostridium difficile infection
colonic function in, 269
intestinal secretion in, 143
Cocaine- and amphetamine-regulated transcript (CART), 45
function of, 52
in weight loss, 124, 229
Colitis
collagenous, colonic function in, 270
experimental, 5-HT mediated anorexia in, 227–228, 228f
microscopic, colonic function in, 271
Collagenous colitis, 270
Colon, 261–292
absorptive capacity of, 275, 276f–278f, 277–279, 286
absorptive processes in, 261, 262–264, 289
future research in, 280
probiotics and, 289
regulation of, 266–267
electrolyte transport in, 261, 262–265
fermentation process in, 272–274, 286, 287
fluid and electrolyte alterations in, 267–272
motor function in, corticotropin-releasing factor receptors and, 32–33, 32f
oral rehydration solution absorption in, 274–279, 276f–278f
secretory processes in, 264–265
future research in, 280
regulation of, 266–267
Colonocytes, 272, 273
Comminuted chicken diet, for chronic diarrhea, 16
Congenital chloride diarrhea, colon function in, 271–272, 288
Corticosteroids, appetite increase with, 239
Corticosterone, neuropeptide Y neuron action and, 49
Corticotropin-releasing factor function of, 31–32
in interventions for anorexia, 181, 189–190
in leptin-cholecystokinin regulation of food intake, 35
post-exercise anorexia and, 209
postprandial satiety and, 209
receptors of antagonists of, 32, 235
in irritable bowel syndrome, 33–34
R121919 as, 34
in brain, 32, 32f
vagal function and, 32–33, 32f
in stress and irritable bowel syndrome, 31–34
in weight loss drug development, 124
Corynebacterium parvum, microvillus membrane injury by, 146
Cow’s milk protein, intolerance to. See also Lactose intolerance
in infants, 11
Crohn’s disease. See Inflammatory bowel disease
Cryptosporidiosis
antimicrobial treatment of, 248, 249
intestinal fluid secretion in, 144
Cyclic adenosine monophosphate (cAMP)
colonic actions of, 266, 267
in interventions for anorexia, 176–177
Cyclic nucleotides, in regulation of ion flux, 164–165
Cyclooxygenase inhibitors
   in interventions for anorexia, 180
   intestinal fluid secretion and, 140
Cyproheptadine, for anorexia, 234
Cystic fibrosis transmembrane conductance regulator, colonic chloride secretion and, 138, 264, 265, 267
Cytokine(s), pro-inflammatory
   in anorexia, 172f, 173–174, 223–225, 224f
   duration of effect of, 233
   pharmacologic intervention for, 174–180, 188–189, 191–192
   gastrointestinal effects of, 233
   signaling of to central nervous system, 179–180, 225–226
   sites of action of, 174
   synergistic action of, 225
Cytokine knockout mice, 173

D
Dantrolene, in interventions for anorexia, 177–178
Dehydration, 17–30. See also Diarrhea; Fluid and electrolytes
   breastfeeding and, 27, 249–250
   in children, 167, 242–243, 245–246, 246t
   classification of, 17, 18t
   definition of, 17
   in developing countries, 17–20, 18t, 19f, 22
   extracellular fluid in, 161
   gastrointestinal fluid loss and, 133, 134, 136, 138. See also Fluid secretion, small intestinal
   hypernatremic, 167
   oral rehydration solutions for, 75–78, 76t, 77t. See also Oral rehydration solutions
   in severely malnourished children, 245–246, 246t, 258
   symptoms with, 17, 18t
2-Deoxy-D-glucose, 211

Depression, irritable bowel syndrome and, 33
Developing countries
   childhood diarrhea in, 1–16
   dehydration in, 17–20, 18t, 22, 29f
   diet in
      chronic diseases and, 95–97, 291, 292
      colonic carbohydrate fermentation and, 274
   malnutrition in, treatment options for, 258
   nutritional transition in, 87–89
   obesity in children in, 291
   zinc deficiency in, 250, 251t, 252, 259
Dexamethasone, in interventions for anorexia, 179
Dexfenfluramine, postprandial satiety and, 209
Diabetes mellitus
   brain changes with, 43
   in Chile, 99
   gastroparesis of, blood glucose levels in, 37–38
   insulin in, neuropeptide Y neuronal system and, 49, 58
   in Latin America, 91, 92f, 96
   in adolescents, 99
   prevention program for, 128–129
   risk of, birth weight and, 101–102
   streptozotocin model of, 42
   weight loss and, 130
Diarrhea
   acute
      assessment of, 242–243
      in children, 241–260
      chronic diarrhea and, 3, 4t, 5, 6, 7f
      colonic function in, 268–270
      dehydration with, 17–30, 18t
      micronutrient supplements for, 250–253
      mortality from, 241
      noninfectious, 28–29
      nutritional support for, 249–250
      oral rehydration solutions for, 72, 73, 74, 243–245, 244t, 245t
      hypoosmolar, 74–78, 75t, 76t, 77t
      resistant starch, 246–247
treatment of
  antimicrobial therapy for, 5–6, 16, 28, 247–249
  fluid and electrolyte replacement in, 242–245
goals in, 241, 241t
  initial, 5–6, 6t
  probiotics for, 253–254, 253t, 259
  vitamin A for, 252, 252t
  zinc supplements for, 250–252, 251t
WHO classification of, 242
AIDS-based, 6–7
  anorexia with, treatment for, 236–237
  cholera. See Cholera, diarrhea in chronic
  antibiotics for, 3, 14, 15
  causes of, 1, 2t, 7–8
  in children, 1–16
  definition of, 1
  diagnosis of, 8, 9t
  dietary management of, 9–11, 10f, 11f, 12–13, 12t, 16
  epidemiology of, 1
  nature of, 152
  newer or rarer groups of, 6–8
  pathophysiology of, 6, 7f
  presentation of, 23–24
  risk factors for, 2–5, 2t
  treatment of, 8–12, 24
  antimicrobial, 3, 14, 15
dietary, 12–13, 12t
colon in, 274–279, 276f–278f
  congenital chloride, colon function in, 271–272, 288
  dehydration from, 17–30, 18t. See also Dehydration
  in developing countries, 2t, 7–8, 7t, 8t, 28, 29
  vs. developed countries, 2t
duration of, absorption efficiency of oral rehydration therapy and, 70–71
dysentery and
  antibiotic treatment of, 15
  in children, treatment of, 247–248
  identification of, 247
  in infants, low birth weight and, 27–28
  literacy rate of mother and, 27
  in Middle East, 7–8, 7t, 8t
  mortality from, 17–20, 18t, 19f, 29
  age and, 259
  nutritional status and, 23, 23t
  reduced, 24
  rotavirus, 3, 22, 27
  colonic function in, 268–269
  vaccines for, 22, 26–27, 29
  transmission of, 30
  viral, 22, 80
Diet
calcium in, weight loss and, 121–122, 127
cardiovascular disease and, 97
for chronic diarrhea, 9–11, 10f, 11f, 12–13, 12t, 15, 16
chronic diseases and, in Latin America, 95–97
energy-dense, in developing countries, 88
energy expenditure and, in men and women, 197
food manufacturers and, 102
lactose-containing
  for acute diarrhea, 10–11, 250
  for chronic diarrhea, 15, 16
  colonic absorption and, 287, 288–289
milk-cereal, for chronic diarrhea, 15, 16
mortality and, in Latin America, 89–91, 90t
for obesity control, 120–122
palatability of, weight reduction and, 120
physical inactivity and, in Latin America, 91
starchy, in developing countries, colonic carbohydrate fermentation and, 274
Digestive processes
  appetite and satiety in, 107–110
  control circuits in, 107–108
  small intestinal nutrients in, 108–110
  control of nutrient intake by, 103–117
  gastric acid secretion in, 103–104
  pancreatic secretion in, 104–107
  regulation of, 102, 104f
Diltiazem, in interventions for anorexia, 177
Disability-adjusted life years, in Latin America, 92, 93f, 94, 94t
Dorsal vagal complex, neurons in, glucose concentration and, 36
Dorsomedial hypothalamic nucleus, in energy homeostasis, 47
Down syndrome, energy expenditure and, obesity and, 199–200
Drugs. See also Antibiotics
   antianorexic, potential targets of, 174–180, 182, 188–189, 191–192
   antidiarrheal, 3, 5–6, 6t, 14, 15, 16, 28, 247–249. See also names of specific drugs
   potential, 150–151
   antiobesity, 122–124
Dysentery
   in children, treatment of, 247–248
   diarrhea and, antibiotic treatment of, 15
   identification of, 247

E
Egg-laying hormone, 64
Electrolytes. See also specific agent, e.g., Sodium
   absorption and secretion of colonic, 266–267
   small intestinal, 136, 138, 164
   transport of colonic, 262–265
   small intestinal, 162–166
Encephalitozoon cuniculi infection, diarrhea with, antimicrobial treatment of, 248
Energy-dense diets, in developing countries, 88
Energy expenditure
   in acquired immunodeficiency syndrome, 221, 222f
   activity-induced, in men and women, 197
   components of, 195, 196f
   diet-induced, in men and women, 197
   in etiology of obesity, 198–201
   in children, 199
   gender differences in, 196–198, 197f
   total vs. resting, in cancer, 44
Energy homeostasis, 195. See also Food intake, regulation of; Satiety carbohydrate fermentation in colon and, 272
   cholecystokinin and, 58–59
   in elderly, 202–203, 203f
   hypothalamic control of, 45–47, 46f, 205–206
   glucose-sensing neurons in, 55
   leptin-cholecystokinin regulation and, 34–35, 47, 48, 56–58, 109
   melanin-concentrating hormone in, 53–55, 54f
   melanocyte-stimulating hormones in, 50–52
   neural pathways in, 55–59
   neuropeptide Y in, 48–50, 49f
   neurotransmitters and peptides in, 48–55
   orexins in, 52–53
   insulin and, 58
   leptin and, 56–58, 64
   medullary influences on, 47–48
   metabolism and, 195–196, 197f
   neural pathways transmitting signals about, 55–59, 107–108
   in anorexia, 31–39, 179–180, 225–226
   application of, 59–60
   neuroanatomy of, 45–47, 46f
   regulation of, 45–67
   vagally controlled functions in, 34–35, 35–38, 36f, 47, 48. See also Vagus nerve
Energy intake, in acquired immunodeficiency syndrome, 221, 222f
Energy metabolism
   gender differences in, 196–198, 197f
   regulation of energy balance and, 195–196, 197f
Enkephalin inhibitors, in anti-diarrheal agents, 151
Entamoeba histolytica infection, antimicrobial treatment of, 248
Enteral feeding, diarrhea with, colonic function in, 271
Enteric nervous system, 31, 152. See also Energy homeostasis
  in anorexia, 31. See also Anorexia
  in cancer cachexia, 38
  colonic secretion and, 270
  heat-stable and heat-labile enterotoxins in, 138–139, 152
  intestinal fluid secretion and, 140–143
  neurotransmitters of, 141t
Enterocyte(s)
  chloride ion secretion and, 136, 137f, 138
  enterotoxins and, 138–139
  water balance and, 161
Enterocytozoon bieneusi infection, diarrhea with, antimicrobial treatment of, 248
Enteropathogens, in acute and chronic diarrhea, 3, 4t
Enterostatin, weight loss drug development with, 124
Enterotoxin(s)
  bacterial, 137t
  chloride ion secretion activated by, 138–139
  cholera, 136
  enteric nervous system and, 152
  heat-labile, 152
  heat-stable, 152
  colonic function with, 269–270
  intestinal smooth muscle effects of, 148
Enzymes, pancreatic secretion of, 105–107
Ephedrine/caffeine, 123
Epithelial sodium channel, 263
  colonic regulation of, 266, 267
Escherichia coli
  enteropathogenic
    mechanism of diarrhea due to, 153
    microvillus membrane injury by, 146
  enterotoxigenic
    diarrhea with, 3
    colonic function in, 269–270
    intestinal fluid secretion and, 142–143
    heat-labile toxins of, chloride ion secretion and, 138
    heat-stable toxins of, chloride ion secretion and, 138–139
Escherichia coli O157, commercial food processing methods and, 25–26
Ethnic groups, obesity development in, 200–201
Etomoxir, 211
Exercise
  cardiovascular disease and, 97
  obesity prevention and, 202
  weight reduction and, 122
Extracellular fluid, 155
  in dehydration, 161
  volume of, sodium and potassium regulation and, 156, 157
F
Fast foods, health policy and, 102
Fat(s)
  body
    accumulation and distribution of, 218, 219
    gender differences in, 198
    leptin in, 198–199
    visceral, 199, 219
dietary, in obesity control, 120
digestion of, in gastrointestinal functions, 106f
food intake regulation by, 109
  intake of, regulation of, 65–66
  non-absorbable, obesity treatment and, 217
  satiety and, 217
Fatty acids
  body weight gain and, 128
  cholecystokinin release and, 105, 106, 114
  long-chain
    in cholecystokinin release, 105, 106
    food intake regulation and, 109
    in malabsorption syndromes, colonic function in, 271
Fatty acids (contd.)
medium-chain, in malabsorption syndromes, 271
omega-3, in cancer patients, weight loss and, 238
oxidation inhibitors of, 211
short-chain carbohydrate fermentation in colon and, 272, 273
colonic absorption and, 262–264, 277–279, 277f, 278f, 287
colonic secretion regulation and, 267 in enteral feeding, 271
fluid and electrolyte regulation and, 167
oral rehydration solutions with resistant starch and, 246, 247
probiotics and, 289
small intestinal effects of, 286, 287
Fecal-oral route of infection, 22
Feeding. See also Appetite; Satiety in acute illness, 239–240
in infants and children, 133, 134f, 261–262
glucose-sensing neurons in, 55
hypothalamic influences on, 45–47
short-term regulation of, orexin activity and, 53
Fermentation, colonic, 272–274
Fiber, in obesity control, 121
Flavor, sensory satiety and, 206–207
Fluid(s)
homeostasis of in gastrointestinal tract, 133, 134, 134f, 135f, 160–166
in infants and children, 133, 134f, 155–170
intravenous in children, 242–243
for dehydration, 80
hypoosmolar oral rehydration solutions and, 76, 77–78
for severe diarrhea, 260
loss of, small intestinal, 134, 136, 138
Fluid and electrolytes. See also names of specific electrolytes
balance of, in infants and children, 155–170
gastrointestinal regulation of, 160–166 in colon, 267–272
small intestinal structure and, 160–162, 161f
replacement of in acute diarrhea, 242–245
in chronic diarrhea, 8–9
Fluid secretion, small intestinal decreased, 145–148
increased chloride ion secretion in, 136, 137f, 138
endogenous secretagogues in, 139–140
enteric nervous system in, 140–143
enterotoxin-induced, 138–139
mucosal inflammation and, 143–145
Food(s) glycemic index and, 129–130
palatability of, cannabinoid receptors and, 66
taste of, sensory satiety and, 206–207
Food allergies, diarrhea and, 28–29
Food intake. See also Energy homeostasis; Satiety
future research topics in, 212
metabolic regulation of liver in, 211, 216
obesity and, 195–220
regulation of in anorexia. See Anorexia brain-gut neural feedback loop in, 55–59, 107–108
cholecystokinin in, 113–114
gastrin-releasing hormone in, 113
hypothalamic areas and, 45–47, 46f, 205–206
by leptin-cholecystokinin through vagal afferent pathway, 34–35, 47, 48, 56–58, 109
obesity and, 204–206, 205f
small intestinal nutrient effects in, 108–110
water intake associated with, 169
Food processing (commercial), Escherichia coli O157 infection and, 25–26
Formula(s), infant, diarrhea and, 10–11
Fos technique, 42
Fructo-oligosaccharides, colonic absorption and, 279
Fructose, in oral rehydration solutions, 84
Furazolidone, for giardiasis diarrhea, 248
G
Galanin
  in anorexia, 229
  colonic secretion and, 270
  satiety and, 209
Gastric acid
  pancreatic secretions regulated by, 107
  secretion of, phases of, 103–104
Gastric distension, food intake regulation and, 108, 109
Gastric emptying
  corticotropin-releasing factor receptors and, 32, 32f
  postprandial satiety and, 208
Gastric motility
  corticotropin-releasing factor receptor and, 33
  hyperglycemia and, in diabetes, 37–38
Gastrin, in gastric acid secretion, 104
Gastrin-releasing peptide (GRP), in food intake inhibition, 113
Gastroenteritis. See also Diarrhea
  in children, 20–23
  causes of, 21–22, 21f, 22f
  in developed and developing countries, 19–22, 21f, 22f
  nutritional status and, 23
  transmission of, 22
Gastrointestinal function, vagal regulation of, blood glucose concentration and, 35–38, 36f
Gastrointestinal infections. See Infection(s)
Gastroparesis, of diabetes mellitus, blood glucose levels in, 37–38
Ghrelin
  as satiety signal, 59
  weight loss drug development with, 124
Giardiasis
  cholecystokinin release in, 233
  diarrhea in, 14, 153
  antimicrobial treatment of, 248
Glucagon-like peptide
  food intake regulation by, 113
  in interventions for anorexia, 181
  physiologic actions of, 110t
  postprandial satiety and, 113, 208
  release of, stimulation of, 115
  as satiety signal, 108, 109–110, 114, 116
  weight loss drug development with, 124
Glucocorticoids
  colonic sodium absorption and, 266
  in interventions for anorexia, 179
Glucose
  in diabetes
    brain-gut axis and, 42–43
    in gastroparesis, 37–38
    in food intake regulation, 208, 210
    in oral rehydration solutions, 70, 77–78
      with amino acids, 70, 71
      vs. cereal-based solutions, 72–74
      hypoosmolar, 74, 75, 75t, 77–78
      sodium absorption coupled with, 69
    in vagal regulation of gastrointestinal function, 35–38, 36f
  glucose-responsive neurons
    in energy homeostasis, 55
    orexin neurons and, 55, 56f
  glucose-sensitive neurons
    in energy homeostasis, 47, 55
    orexin activity and, 53, 54f
  glucose-sodium ratio, in oral rehydration solutions, 84–85
  glucose transporter (GLT), in small intestine, 163
  glucostatic theory, of food intake, 210
  L-Glutamine, in oral rehydration solutions, 70, 71, 72
  glycemic index
    food choice and, 129–130
    vs. glycemic load, 129
  glycemic load, 121
  Glycine, in oral rehydration solutions, 70, 71, 72
  glycogenostatic theory, of food intake, 211
  Granisetron, intestinal secretions in cholera and, 142
  Growth hormone secretagogue receptors, 59
  Growth hormone secretion, ghrelin action and, 59
  Guanylate cyclase, enterotoxin action and, 139
Guar gum, colonic absorption and, 279
Gut lumen, osmotic forces in, oral
rehydration solution
formulations and, 70

H
Handwashing, in prevention of diarrhea, 14
Health-adjusted life expectancy, 102
in Latin America, 94–95, 95t
Health policy
in developing countries, 292
fast food availability and, 102
physical activity availability in schools
and, 218
Height, leptin and, 65
Hepatic afferent nerves, in food intake
regulation, 211
Hepatitis, anorexia with, 238–239
Hexamethonium, 141
Home use, of oral rehydration solutions, 84
Hormones
in food intake regulation, 55–59,
107–110, 113
mediating anorexia, 226–230, 228f
Human immunodeficiency virus infection, diarrrhea with, antimicrobial
treatment for, 249
Hunger and satiety. See also Satiety
energy homeostasis regulation in. See also Energy homeostasis
hypothalamic pathways in, 48–55
medullary areas involved in, 47–48
neural signaling circuits in, 55–59,
107–110
neuroanatomy involved in, 45–47,
46f
neurotransmitters and peptides in, 48–55
5-Hydroxytryptamine
in anorexia, 227–229
interventions for, 180–181
agonists of, 234
in cholera, 141–142
in healthy state, 153
in intestinal fluid secretion in disease,
139–140
in irritable bowel syndrome, 151
postprandial satiety and, 208–209
as target for anti-secretory agent,
150–151
Hyperglycemia, in diabetes, gastric
motility and, 37–38
Hypernatremia
in acute diarrhea, 242
dehydration with, in infants, 167
risk of, with oral rehydration solutions,
243
Hyperphagia
agouti-related peptide and, 51
neuropeptide Y and, 48, 49
orexin activity and, 53. See also
Orexin(s)
stress-related, endogenous opioids and,
209
Hyperphagic (eating) hormone, 64
Hypersensitivity, immediate,
immunoglobulin E-mediated, 144
Hypertension
cardiovascular disease and, 97
weight loss and, 131
Hypokalemia, in acute diarrhea, 242
Hyponatremia, in acute diarrhea, 242
Hypothalamus
neurotransmitters and peptides of
in energy homeostasis, 48–55
in food intake regulation, 205–206
cholecystokinin in, 58–59
ghrelin in, 59
insulin in, 58
leptin in, 56–58
in interventions for anorexia, 181–182
Hypothalamic neurochemical pathways
in energy homeostasis, 48–55
in food intake regulation, 205–206
cholecystokinin in, 58–59
ghrelin in, 59
insulin in, 58
leptin in, 56–58
in interventions for anorexia, 181–182
Hypothalamic neurochemical pathways
in energy homeostasis, 48–55
in food intake regulation, 205–206
cholecystokinin in, 58–59
ghrelin in, 59
insulin in, 58
leptin in, 56–58
Hypothalamus
neurotransmitters and peptides of
in energy homeostasis, 48–55
in food intake regulation, 205–206
cholecystokinin in, 58–59
ghrelin in, 59
insulin in, 58
leptin in, 56–58
Hypothalamic neurochemical pathways
in energy homeostasis, 48–55
in food intake regulation, 205–206
cholecystokinin in, 58–59
ghrelin in, 59
insulin in, 58
leptin in, 56–58
Hypothalamus
neurotransmitters and peptides of
in energy homeostasis, 48–55
in food intake regulation, 205–206
cholecystokinin in, 58–59
ghrelin in, 59
insulin in, 58
leptin in, 56–58
Hypothalamic neurochemical pathways
in energy homeostasis, 48–55
in food intake regulation, 205–206
cholecystokinin in, 58–59
ghrelin in, 59
insulin in, 58
leptin in, 56–58
I

Igmesine, cholera intestinal secretions and, 142, 143

Immediate hypersensitivity reactions, immunoglobulin E-mediated, 144

Immunocompromised status, diarrhea with antimicrobial treatment of, 248 chronic, 3, 15

Immunoglobulin E-mediated immediate hypersensitivity reactions, intestinal fluid secretion and, 144

Immunomodulators for cytokine signaling in anorexia, 225–226. See also Cytokine(s), pro-inflammatory
for obesity, 188

Indians, obesity development in, 200–201

Indinivir, for cryptosporidiosis diarrhea, 249

Indomethacin, for anorexia, 180

Infants. See also Neonates diarrhea in chronic, 2 intestinal permeability and, 10 fluid and electrolyte balance in, 155–170 rice-based oral rehydration solutions in, 73

Infection(s). See also names of specific infections, e.g., Shigellosis acute inflammatory cell infiltrates in, 145 bacterial in developed and developing countries, 21–22 microvillus membrane injury by, 146 models of, 171 diarrhea with, 3, 4t antibiotics for, 5–6, 28 enteric in children, 20–23 in developing and developed countries, 19–22, 21f, 22f impaired fluid absorption in, 136, 136t morbidity and mortality from, 19–20, 19f presentation of, 23–24 small bowel bacterial overgrowth and, 15–16 villous atrophy with, 146–147 intestinal fluid secretion in, 144 irritable bowel syndrome and, 151 parasitic, in developing countries, 21–22 protozoal, 147, 248

Inflammation, mucosal growth deficit and, 237–238 intestinal fluid secretion and, 143–145, 145t

Inflammatory bowel disease diarrhea with, colonic function in, 270 models of, 171 Infliximab, anorexia and, 234

Intussusception, after rotavirus vaccination, 26
Ion channels, in small intestine, 163
Ion flux
intercellular regulators of, 165
intracellular regulators of, 164–165
IRAK (Ser/Thr kinase), in interventions for anorexia, 175
Irritable bowel syndrome
corticotropin-releasing factor in, 31–34
intestinal infection and, 151
pharmacologic therapy of, 33–34
symptoms of, 33
Ischemic heart disease, in Latin America, 91, 92f
Isospora infection, diarrhea with, antimicrobial treatment of, 248
J
Juxtaglomerular apparatus, sodium regulation and, 157, 158f
K
Kaopectate, 286
Ketanserin, cholera intestinal secretions and, 142
Kidney
damaged, intestinal compensatory mechanisms and, 168
function of, in protein malnutrition, 168
sodium regulation and, 157–158, 158f
Kwashiorkor, chronic diarrhea and, 4f
L
Lactobacilli, for diarrhea, 26, 28, 253
Lactose intolerance
in acute diarrhea treatment, 10, 11, 250
in chronic diarrhea treatment, 15, 16
colonic absorption and, 287, 288–289
Lactulose–mannitol ratio, in diarrhea, 10, 12
Lateral hypothalamic area
in energy homeostasis, 47
food intake regulation and, 205–206
Latin America
demographic data in, 88, 88t
diet-related chronic diseases in, 95–97
disability-adjusted life years in, 92, 93f, 94, 94t
health-adjusted life expectancy in, 94–95, 95t
lifestyle changes in, disease risk factors and, 89–91, 90t
mortality in, 91–92, 92f
nutritional changes in, 87–89
socioeconomic indicators in, 88, 89t
Leptin
administration of orexin activity and, 53
weight loss with, 64–65, 123
in anorexia from chronic disease, 227
in fat accumulation and distribution, 198–199
in feeding regulation, 34–35, 47, 48, 56–58, 109
function of, 34–35, 57–58
in general obesity or central obesity, 65
height and, 65
melanocortin system interaction with, 51
mutations of, 57
neuropeptide Y action and, 49, 50
receptors of expression of, 57
in gut, in energy homeostasis, 64
Ob-Rb isoform of body weight and, 57
in dorsomedial hypothalamic nucleus, 47
in nucleus tractus solitarius, 48
recombinant human, 59
secretion and transport of, 34
Leukotrienes, intestinal smooth muscle effects of, 148
Life expectancy
at birth, 94, 95, 95t
health-adjusted, in Latin America, 94–95, 95t
Lifestyle changes, in Latin America, mortality and, 89–91, 90t
Lineolic acid, taste of, in studies of obesity, 207–208, 217, 219
Lipase, gastric, in lipid digestion, 105
Subject Index

Lipid mobilizing factor, cancer cachexia and, 43
Lipids, food intake regulation by, 109
Lipopolysaccharide(s), anorexia induced by, 171, 175–176, 180, 223, 224
5-HT antagonists for, 228
pro-inflammatory cytokine action and, 225–226
tolerance to, 190
Lipopolysaccharide binding protein (LBP), in interventions for anorexia, 175
Literacy rate of mother, diarrheal disease in infant and, 27
Liver, in metabolic control of food intake, 211, 216
L-NAME, in intestinal secretions, 140
Locus ceruleus complex, colonic motor function and, 33
Low birth weight, 291
diarrhea in infants and, 27–28

M
Macronutrient absorption, in chronic diarrhea, 9–10, 10f, 11f
Malabsorption syndromes, colonic function in, 271
Malnutrition, children with
dehydration and, 245–246, 246t
diarrhea and, 3, 5, 5f, 12
mortality with, 23, 23t
electrolyte regulation in, 168
kidney function in, 168
in Latin America, 89
rice-based oral rehydration solutions in,
73
treatment options for, 258
Maltodextrins, in oral rehydration solutions, 70, 71, 72
Marasmus
chronic diarrhea and, 5f
feeding in, 240
potassium levels in, 259
treatment options for, 258
Mast cells, inflammatory mediators of, intestinal fluid secretion and, 144, 145t
Meat-processing, Escherichia coli O157 infections and, 25–26
Median eminence, 45–46, 46f
Medications. See Drugs
Medullary influences, on energy homeostasis, 36–37, 47–48
Melanin-concentrating hormone in anorexia, 229
in energy homeostasis, 47, 53–55
receptors for, G-protein-coupled, 54
in weight loss drug development, 124
Melanocortin receptors
antagonists of
effect of, 182, 235
for interleukin-1β induced anorexia, 229
morbid obesity and, 52
subtypes of, 50
dietary obesity and, 66
MC3-R and MC4-R, 48, 50, 51
Melanocortin system, neuropeptide Y interaction with, 51–52
α-Melanocyte-stimulating hormone, 48, 50
anorexia and, 229
in energy homeostasis, 50–52
as target for weight loss drug development, 124
Men, energy metabolism in, 196–198, 197f
Metabolic rate, average daily, in men and women, 197
Metabolism
energy balance regulation and, 195–196, 197f
food intake and, obesity and, 195–220
gender differences in, 196–198, 197f
Metformin, 128, 129
Metronidazole, for diarrhea, 248, 258
Mexico, obesity in, 96
Mianserin, for lipopolysaccharide-induced anorexia, 228
Mice
cytokine knockout, anorexia in, 173
transgenic knockout, obesity and, 65
Micronutrients, loss of, in chronic diarrhea, 12, 15, 23
Microscopic colitis, colonic function in, 271
Microsporidiosis, antimicrobial treatment for, 248, 249
Microvillus membrane, injury to, 146
Milk
- in acute diarrhea treatment, 10–11, 250
  human. See also Breastfeeding
  body weight in children and, 128
  in infant formulas, in diarrhea treatment, 10–11
Milk-cereal diet, for chronic diarrhea, 15, 16
Mineralocorticoids, colonic sodium absorption and, 266
Mortality
- from cancer, in Latin America, 91, 92f
  from diarrhea
  in developed and developing countries, 17–20
  in neonates, 27–28
  nutritional status and, 23, 23t
  reduced, 24
  in Latin America, 89, 91–92, 92f, 97
  chronic diseases and, 95–97
  dietary factors in, 89–91, 90t
Mucosa, intestinal
- in chronic diarrhea, 3, 5
  disruption of, 146–147
  food intake and, 234
  inflammation of, fluid secretion and, 143–145
Muscle wasting, cancer cachexia and, 44
MyD88, in interventions for anorexia, 175

N
Natriuretic peptide, atrial, 157
Nausea and vomiting
- anorexia and, 235
  with new oral rehydration solutions, 80
Neonates. See also Infants
- colonic absorption in, 286, 287
- diarrhea in, mortality with, 27–28
- fluid requirements in, 133, 134f
- oral rehydration solutions for, 83–84
- urine concentration in, 169–170
Neuronal secretory reflex
- in C. difficile infection, 143
- in cholera, 141, 142, 268
- in enterotoxigenic E. coli infection, 143
Neuropeptide(s)
- of arcuate eminence, 45–47, 46f
- mediating anorexia, 226–230, 228f
Neuropeptide Y, 45
- in arcuate nucleus, in energy homeostasis, 48–50, 49f, 58
- in cancer anorexia-cachexia, 229, 233
- in interventions for anorexia, 182
- melanocortin system interaction with, 48, 49f, 51–52
- postprandial satiety and anorexia and, 209
- as target for weight loss drug development, 124
Neurotransmitters
- colonic, 266, 267
- enteric, 141t
- hypothalamic, in energy homeostasis, 48–55
Nitazoxanide
- for cryptosporidiosis diarrhea, 249
- for giardiasis diarrhea, 248
Nitric oxide, 178
- in intestinal fluid secretion in disease, 140, 143
Nonstructural glycoprotein 4, 139, 153
NS-398, in interventions for anorexia, 180
NSP4 (nonstructural glycoprotein 4), 139, 153
Nuclear factor-κB
- in anorectic response, 174
- in interventions for anorexia, 175, 177, 178, 179
Nucleus tractus solitarius
- corticotropin-releasing factor receptor function and, 33
- in energy homeostasis, 47–48
- in regulation of food intake glucose in, 37
  - leptin-cholecystokinin in, 35, 35f
  - satiety information in, 108. See also Satiety
Nutrient(s)
- absorption of, in chronic diarrhea, 9–10, 10f, 11f
  intake of, control of by gut, 103–117.
  See also Food intake, regulation of
small intestinal, in regulation of food intake, 108-110
sodium cotransport of, in intestines, 163
Nutrient-sodium co-transport mechanisms, gastrointestinal fluid absorption by, 135f
Nutritional management
for acute diarrhea, 249-250
for chronic diarrhea, 9-11, 10f, 11f mortality with, 23, 23t
Nutritional transition
in developing countries, 87-89
in Latin America, 98
Nutrition-related noncommunicable disease
in Canada, 91, 92f
in developing countries, 88
in Latin America, 91, 92f, 94t, 95-97

O
Obesity
android vs. gynoid, health risks and, 198-199
body fat accumulation and distribution in, 198-199, 218, 219
breastfeeding and, in Chile, 100
causes of, 218
energy expenditure and, 199-200
ethnicity and, 200-201
longitudinal studies in, 200
in children vs. adults, 95-96
in developing countries, 291, 292
energy metabolism and, 199
measurement standards for, 100-101
parental obesity and, 219
in developing countries, 88, 291, 292
in elderly, 202-203, 203f
energy homeostasis regulation and, 59-60, 198-201
food intake and metabolism and, 195-220
future research topics in, 211-212
gene-environment interactions and, 64, 66-67
in Latin America, 90-91, 95-96
leptin and, 65, 198-199
melanocortin receptor action and, 51
morbid
melanocortin axis activity and, 52
neurobiologic energy homeostasis signaling systems and, 59
treatment of, 203-204
neuropeptide Y and, 49
prevention of, targeting of interventions for, 202
protein intake and, in Chile, 100
treatment of, 119-131, 203-211
by behavior therapy, 119-120
by diet, 120-122
by drugs, 122-124
by exercise, 122
food intake regulation and, 204-206, 205f
by immunomodulating agents, 188
by surgery, 124-125
Ofloxacin, for shigella diarrhea, 248
8-OH-DPAT, for anorexia, 181, 190
lipopolysaccharide-induced, 228
Olestra, 120
composition of, 128
Oligo-deoxynucleotide, in interventions for anorexia, 179
Omega-3 fatty acids, in cancer patients, weight loss and, 238
Ondansetron, cholera intestinal secretions and, 142
Opioids, endogenous, stress-related hyperphagia and, 209
Oral rehydration solutions
absorption efficiency of, 70-71
amino acid-fortified, vs. standard WHO formula, 245
amylase-resistant starch in, 77, 246-247, 250, 285
cereal-based, 71, 72-74
vs. glucose, 72-74
colonic absorption and, 274-279, 276f-278f
composition of, 70, 243
improved formula for, 243-245, 244t, 245t
for dehydration from diarrhea, 69-85
with severe malnutrition, 246
Oral rehydration solutions *(contd.)*

for diarrhea, 5–6, 6t, 24, 27, 69–85, 274–275

efficacy of, 242

fructose or sucrose in, 84

glucose-based

  with amylase-resistant starch, 246–247

  colonic absorption with, 277f, 278f

  for diarrhea, 274–275

  with reduced osmolarity, 74–78, 75t

  glucose-sodium ratio in, 84–85

goals of, 70

home use of, 84

hypoosmolar, 74–78, 75t, 243–245, 244t, 245t, 246, 259–260

in children, 75–77, 76t, 77t

for dehydration in severe malnutrition, 246

efficacy of, 77–78

stool output with, 81–82

vomiting with, 80

improvements in, 69–70

approaches used for, 71–73

for neonates, 83–84

palatability of, 83

rehydration time with, 83

rice-based

  vs. amyloid-resistant starch ORS, 285

  colonic absorption with, 278f, 279

  vs. glucose, 5–6, 6t

  vs. standard WHO formula, 245

starch in

  colonic absorption with, 278f, 279, 285

  for diarrhea in cholera, 246–247, 285

water supply and, 14

Orexin(s)

in energy homeostasis, 47, 52–53, 54f

  receptors of, 52

food and water intake and, 169

neurons of, glucose-responsive neurons and, 55, 56f

Orlistat, 109, 123

restrictions on, 122

Osmolarity, of oral rehydration solutions, 72, 75–76, 76t, 77t, 78, 81–82, 243–245, 244t, 245t, 246, 259–260

glucose-based, 74–78, 75t

Osmotic forces, in gut lumen, oral rehydration solution formulations and, 70

Ouabain, 211

Overeating, compensatory, 190–191

P

Pancreatic cancer, cachexia in, 43

Pancreatic secretions, in digestive process, phases of, 104–107

Parasitic infections

  in developing and developed countries, 21–22

  immediate hypersensitivity reactions to, intestinal fluid secretion with, 144

Paraventricular nucleus

  colonic motor function and, 33

  in energy homeostasis neuroenteral pathways, 36, 47

  glucose-sensing neurons in, 36, 55

  in leptin-cholecystokinin regulation of food intake, 35

Paromomycin, for cryptosporidiosis diarrhea, 249

Pectin, colonic absorption and, 279, 286

Pentoxifylline, for anorexia, 176–177, 189, 225

Pepsin, 105

Peptide(s)

  hypothalamic, in energy homeostasis, 48–55

  postprandial satiety and, 208

  as satiety signals, 34–35, 103, 104f, 107–110. See also Energy homeostasis; Satiety

  Peroxisome proliferator-activated receptors, in interventions for anorexia, 178–179

  Phosphodiesterase, in interventions for anorexia, 176
Physical activity/inactivity
  cardiovascular disease and, 97
  in developing countries, 88, 91
  diet and, in Latin America, 91
  geographical and seasonal component of, 218
  obesity prevention and, 202, 218
  school programs for, 218
  weight reduction and, 122
Polyhydramnios, congenital chloride diarrhea and, 288
Polysaccharides, non-starch, colonic fermentation of, 272, 273
Potassium
  colonic secretion and transport of, 264, 265
  deficiency of, in chronic diarrhea, 9
  levels of
    in marasmus, 259
    ReSoMal rehydration solution and, 260
  small intestinal absorption of, 163–164
  supplements of, in severe malnutrition, 245–246
Prader-Willi syndrome, energy expenditure and, obesity and, 200
Pregnancy, body weight gain with, 203, 204f
Probiotics
  for diarrhea, 26, 28
    acute, 252–253, 253t
    bloody, 259
  short-chain fatty acids in gut and, 289
Pro-opiomelanocortin, 45
  anorexia and, 229
  melanocyte-stimulating hormones derived from, 50
  neuropeptide Y interaction with, in hypothalamus, 48, 49f
  in nucleus tractus solitarius, 48
Propionate, from carbohydrate fermentation in colon, 272, 273, 287
Prostaglandin(s)
  in cholera, 153
  intestinal fluid secretion and, 140, 144
  intestinal smooth muscle effects of, 148
  Prostaglandin E₂
    in anorexia, 180
    intestinal fluid secretion and, 140
  Proteinase-activated receptor type 2, colonic electrolyte regulation and, 267
  Protein intake
    and obesity, in Chile, 100
    weight reduction and, 216–217
  Protein kinase C, colonic sodium absorption and, 266
  Protein kinase G, colonic electrolyte regulation and, 267
  Proteolysis-inducing factor, cancer cachexia and, 43
Protozoal infection
  antimicrobial treatment of, 248
  villous atrophy with, 147
Psychological conditions
  anorexia in, 236
  irritable bowel syndrome and, 33
Q
  Quinacrine, for giardiasis diarrhea, 248
R
  Racecadotril, 151
  Recombinant human leptin, 59
  Renin-angiotensin cascade, 157
  ReSoMal solution
    for dehydrated children with severe malnutrition, 246, 246t, 258
    potassium levels and, 260
  Resveratrol, in experiments on anorexia interventions, 180
  Rice-based oral rehydration solutions, 71, 72–74, 245
    colonic absorption with, 278f, 279
    vs. standard WHO formula, 245
  Rice diet, for diarrhea, 11, 289
    with milk, 250
  Ritanserin, for anorexia, 181
Rotavirus infection
- diarrhea with, 3, 22, 27
- colonic function in, 268–269
- enterotoxins of, chloride ion secretion and, 139
- intestinal secretory neural reflex in, 143
- intestinal villous atrophy with, 147
- macronutrient absorption in, 10f
- vaccines for, 22, 26–27, 29

Roundworm, diarrhea with, 15

S
Salmonellosis, diarrhea with
- antibiotics for, 28
- colonic function in, 269

Satiety. See also Energy homeostasis
- definition of, 107
- food intake regulation and, 107–110, 204–205, 205f. See also Food intake, regulation of brain–gut neural feedback loops in, 107–108
- carbohydrate intake and, 110, 210
- fat-specific, 207–208, 217, 219
- gastrin-releasing hormone in, 113
- by leptin-cholecystokinin, 34–35, 47, 48, 109
- sensory, 207–208
- sensory-specific, 206–207
- serotonin in, 115–116, 208, 209
- small intestinal nutrient effects in, 108–110
- liver function and, 211, 216
- neuronal signaling about, 48–55, 55–59, 107–110
- cholecystokinin in, 58–59, 113–114
- ghrelin in, 59
- glucose in, 47, 55
- in hypothalamic areas, 45–47, 46f, 205–206
- insulin in, 49, 58
- leptin in, 56–58
- in postabsorptive phase, 209–211
- postprandial, 208–209
- Satiety center, 47
- Second messengers, in regulation of ion flux, 164–165

Secretagogues
- colonic, 266
- growth hormone, 59
- small intestinal, 139–140

Secretin, in release of pancreatic secretions, 105, 107

Septona intestinalis infection, antimicrobial treatment of, 248, 249

Serotonin. See also 5-Hydroxytryptamine antagonists of, in interventions for anorexia, 180–181
- postprandial satiety and, 208, 209
- satiety and, 115–116

Serotonin reflex, 152

Serum and glucocorticoid kinase, 266

Sex steroids, female, body fat distribution and, 199

Shigella infection
- antibiotics for, 5–6, 248
- chronic diarrhea and, 3, 4f
- colonic absorption in, 269, 275, 277f
- macronutrient absorption in, 11f

Short bowel syndrome, 271, 288

SHU9119 (melanocortin receptor antagonist), for anorexia, 182, 229

Sibutramine, 123

Sleeping metabolic rate, in men and women, 196–197, 197f

Sleep-wake functions, orexin activity and, 53

Small intestine
- absorption-secretion relationship in, 136, 138, 164, 226, 287
- bacterial overgrowth in, in chronic diarrhea, 15–16
- cells of, 161
- electrolyte transport in mechanisms of, 162–164
- regulation of, 164–166
- fluid absorption in, 134, 135f, 145
- fluid secretion in decreased, 145–148
- increased endogenous secretagogue action and, 139–140
- enteric nervous system and, 140–143
enterotoxin action and, 137t, 138–139
mucosal inflammation and, 143–145
motor dysfunction of, fluid loss and, 147–148
mucosal architecture of
in chronic diarrhea, 3, 5
- disruption of, 146–147
mucosal damage in, food intake and, 234
mucosal inflammation in, fluid secretion and, 143–145
permeability of, in diarrhea in infants, 10
stimulation of pancreatic digestive secretions and, 105–107
structure and function of, 161, 161f
water transport in, mechanisms of, 162
Smoking, cardiovascular disease and, 97
Socioeconomic growth, in Latin America, health effects of, 88, 89t
Sodium, in oral rehydration solutions, 243, 244, 245, 245t
hypoosmolar, 75, 76, 77, 81, 82
Sodium balance, regulation of, 156–159
Sodium chloride absorption of
- colonic, 261, 262–264
  - aldosterone regulation of, 266
  - short-chain fatty acids and, 262
  - of water, 262–263
- small intestinal
  - by enterocytes, 134, 135f
  - glucose and, 69
  - of short-chain fatty acids, 286
vs. potassium, in body water, 156
reabsorption of, by parts of kidney, 158, 158f, 159
regulation of, 155
secretion of, colonic, 264–265
transport of
  - colonic, 276f
  - via exchange mechanisms, 163
water balance and, regulation of, 155–158, 157f, 158f
Sodium-chloride cotransport of nutrients with
  - colonic, 264, 265
  - small intestinal, 163
Sodium-hydrogen exchanger
  - colonic regulatory action of, 263, 266, 267
  - in fluid balance, 134, 135f
Sodium-proton antiporter, 159
Sodium pump, 156, 158–159, 159f, 162–163
  - in colon, 262–263
Sodium salicylate, anorexia and, 223
Somatostatin, corticotropin-releasing factor receptors and, 32
Starch
  - amylase-resistant
    - colonic fermentation of, 77, 250, 272–273
    - in oral rehydration solutions, 77, 246–247
    - in cholera, 246–247
  - energy-dense, 290
  - resistant, colonic absorption of, 277–279, 277f, 278f, 288
Starvation, vs. cachexia, 191
Stomach. See also Gastric
  - in postprandial satiety, 208
Stool output, oral rehydration therapy and, 70, 81–82
Streptozotocin, in diabetes, 42
Stress
  - corticotropin-releasing factor and, 31–34, 209
  - food intake and, 209
  - irritable bowel syndrome and, 33
Stress hormones, in disease-related anorexia, 235
Substance P
  - in intestinal fluid secretion in disease, 140, 142, 143, 151
  - as target for potential anti-secretory agent, 151
Sucrose, in oral rehydration solutions, 84
Superoxide, 178
Suppressors of cytokine signaling, in interventions for anorexia, 179–180
Surgery, for obesity control, 124–125
Syndrome X, inflammatory markers and obesity and, 66–67
### T

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taste, of food, sensory satiety and</td>
<td>206–207</td>
</tr>
<tr>
<td>T cells, in villous atrophy</td>
<td>147</td>
</tr>
<tr>
<td>Temperature</td>
<td></td>
</tr>
<tr>
<td>- ambient, obesity and</td>
<td>218</td>
</tr>
<tr>
<td>- body, anorexia and</td>
<td>223</td>
</tr>
<tr>
<td>Tetracycline, for cholera diarrhea</td>
<td>248</td>
</tr>
<tr>
<td>Tetrodotoxin</td>
<td>141, 143, 152</td>
</tr>
<tr>
<td>Thermogenesis</td>
<td></td>
</tr>
<tr>
<td>- insulin and</td>
<td>58</td>
</tr>
<tr>
<td>- leptin levels and, in different disease states</td>
<td>66</td>
</tr>
<tr>
<td>- neuropeptide Y and</td>
<td>48, 49</td>
</tr>
<tr>
<td>Thermoregulation, in men and women</td>
<td>198</td>
</tr>
<tr>
<td>Thirst</td>
<td></td>
</tr>
<tr>
<td>- assessment of</td>
<td>242</td>
</tr>
<tr>
<td>- water balance control and</td>
<td>160</td>
</tr>
<tr>
<td>Thyrotropin-releasing hormone, in energy imbalance</td>
<td>37</td>
</tr>
<tr>
<td>Tinidazole, for giardiasis diarrhea</td>
<td>248</td>
</tr>
<tr>
<td>Toll-like receptors, in interventions for anorexia</td>
<td>175–176</td>
</tr>
<tr>
<td>Topiramate, weight loss with</td>
<td>123</td>
</tr>
<tr>
<td>Total body water</td>
<td>155</td>
</tr>
<tr>
<td>Toxins. See also Enterotoxin(s)</td>
<td></td>
</tr>
<tr>
<td>- heat-labile and heat-stable</td>
<td>138–139</td>
</tr>
<tr>
<td>- enteric nervous system and</td>
<td>152</td>
</tr>
<tr>
<td>Trace elements, in diarrhea treatment</td>
<td>12</td>
</tr>
<tr>
<td>Transcription factors, in interventions for anorexia</td>
<td>175, 178–179</td>
</tr>
<tr>
<td>Translocated intimin receptor</td>
<td>146</td>
</tr>
<tr>
<td>Traveler’s diarrhea</td>
<td>247, 279</td>
</tr>
<tr>
<td>Trimethoprim-sulfamethoxazole, for infectious diarrhea</td>
<td>248, 249</td>
</tr>
<tr>
<td>Trinitrobenzenesulfonic acid</td>
<td>171</td>
</tr>
<tr>
<td>- in experimental anorexia</td>
<td>223, 224, 224f</td>
</tr>
<tr>
<td>Troglitazone</td>
<td>128, 129</td>
</tr>
<tr>
<td>Tropical enteropathy, small intestinal damage in</td>
<td>234</td>
</tr>
<tr>
<td>Tropisetron, cholera intestinal secretions and</td>
<td>142</td>
</tr>
<tr>
<td>Tryptophan</td>
<td></td>
</tr>
<tr>
<td>- anorexia and</td>
<td>38</td>
</tr>
<tr>
<td>- appetite and</td>
<td>64</td>
</tr>
<tr>
<td>- postprandial satiety and</td>
<td>208–209</td>
</tr>
<tr>
<td>Tumor markers, cancer cachexia and</td>
<td>43</td>
</tr>
<tr>
<td>Tumor necrosis factor-α</td>
<td></td>
</tr>
<tr>
<td>- antagonist of</td>
<td>233</td>
</tr>
<tr>
<td>- in experimental anorexia</td>
<td>223–225</td>
</tr>
<tr>
<td>- in interventions for anorexia</td>
<td>173, 176, 177, 178, 188–189</td>
</tr>
</tbody>
</table>

### U

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ulcerative colitis. See Inflammatory bowel disease</td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection, chronic diarrhea and</td>
<td>16</td>
</tr>
<tr>
<td>Urine, concentration of, in neonates and malnourished children</td>
<td>169–170</td>
</tr>
<tr>
<td>Urocortin, 32</td>
<td></td>
</tr>
<tr>
<td>- in weight loss drug development</td>
<td>124</td>
</tr>
</tbody>
</table>

### V

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccines, for rotavirus infection</td>
<td>22, 26–27, 29</td>
</tr>
<tr>
<td>Vagus nerve</td>
<td></td>
</tr>
<tr>
<td>- afferent pathways of</td>
<td>226</td>
</tr>
<tr>
<td>- in anorexia signaling</td>
<td>34–35, 47, 48</td>
</tr>
<tr>
<td>- in satiety signaling</td>
<td>107–108</td>
</tr>
<tr>
<td>- for satiety signals</td>
<td>59</td>
</tr>
<tr>
<td>- cholinergic pathways of, in stimulation of pancreatic digestive secretions</td>
<td>105, 106</td>
</tr>
<tr>
<td>- efferent pathways of</td>
<td></td>
</tr>
<tr>
<td>- in blood glucose regulation of gastrointestinal function</td>
<td>35–38, 36f</td>
</tr>
<tr>
<td>- corticotropin-releasing factor receptor function and</td>
<td>32–33, 32f</td>
</tr>
<tr>
<td>- Vasoactive intestinal polypeptide cholera toxin and</td>
<td></td>
</tr>
<tr>
<td>- colonic function and</td>
<td>268</td>
</tr>
<tr>
<td>- intestinal secretions with</td>
<td>142</td>
</tr>
<tr>
<td>- colonic action of</td>
<td>267, 268</td>
</tr>
<tr>
<td>- receptor of, as target for anti-secretory agent</td>
<td>151</td>
</tr>
<tr>
<td>Ventromedial hypothalamic area, food intake regulation and</td>
<td>47, 205–206</td>
</tr>
<tr>
<td>- and</td>
<td></td>
</tr>
</tbody>
</table>
Verapamil, in interventions for anorexia, 177–178
Villous atrophy, in small intestine, fluid loss and, 146–147
Viral diarrhea
  in developing and developed countries, 22
  oral rehydration therapy for, vomiting with, 80
Vitamin A
  for acute diarrhea, 252, 252t
  in malnourished children, 259
Vomiting
  anorexia and, 235
  with new oral rehydration solutions, 80

W
Water. See also Fluid(s)
  body
    maintenance of, 155
    regulation of, 159–160
  colonic absorption of, 261
  intestinal regulation and transport of,
    133, 134, 134f, 135f, 161–162, 161f
  reabsorption of, by parts of kidney, 159
Water intake, thirst and, 160
Water loss, insensible, 160
Water supply, 14, 22
Weight
  pregnancy and, 203, 204f
  quality of life and, 129

Weight gain
  with feeding in acute illness, 240
  after severe malnutrition, 192, 193
Weight loss
  in chronic disease, mechanisms of, 221, 222f
  comorbidities and, 130–131
  leptin and, 64–65
  long-term follow-up of, 130
  medications promoting, 122–124
  protein intake and, 216–217
Women, energy metabolism in, 196–198, 197f
World Health Organization
  intravenous fluid therapy of, 243
  oral rehydration solutions of. See Oral rehydration solutions
  ReSoMal solution of, in malnourished children, 246, 246t, 258, 260
Worm infestation, hunger and satiety with, 217

Z
Zinc deficiency, 250, 252
  in malnourished children, diarrhea deaths and, 259
Zinc supplements, for diarrhea, 12, 15, 23, 26
  acute, in developing countries, 250–252, 251t
Zonula occludens toxin, 268
  enterotoxin action and, 139